We developed a practical framework to construct digital twins for predicting and optimizing triple-negative breast cancer (TNBC) response to neoadjuvant chemotherapy (NAC). This study employed 105 TNBC patients from the ARTEMIS trial (NCT02276443, registered…
Continue Reading
Background: Numerous mobile apps have been developed for patients with cancer. However, there is still no comprehensive app for patients with breast cancer that integrates evidence-based medical information, psychological support, and schedule management through…
Continue Reading
Evinova, a clinical trial technology company, is partnering with Quantum Leap Healthcare Collaborative (QLHC) to integrate Evinova’s remote patient monitoring (RPM) offering into I-SPY 2.2, a platform trial that provides a framework to study…
Continue Reading
Patient Satisfaction Study Reveals Groundbreaking Results
A landmark independent study published in the peer-reviewed journal Gland Surgery has revealed that breast cancer patients who underwent cryoablation treatment reported significantly higher satisfaction levels compared to those…
What You Should Know:
– GE HealthCare has unveiled Invenia™ Automated Breast Ultrasound (ABUS) Premium, a cutting-edge 3D ultrasound system designed to revolutionize breast cancer screening for women with dense breast tissue.
– The technology integrates…
Continue Reading
Up to 8% of cancer patients refuse chemotherapy because they don’t want to lose their hair. Of course, hair loss can cause immense damage to a person’s self-esteem — but it can also strip…
Continue Reading
What You Should Know:
– The American Cancer Society (ACS) and Layer Health, an innovator in AI-driven healthcare technology, have announced a multi-year collaboration aimed at accelerating cancer research. This partnership will leverage large language…
Continue Reading
Study Confirms AI Boosts Cancer Detection Rates
Lunit’s groundbreaking research published in Nature Communications has validated the effectiveness of AI-powered mammography screening in real-world settings. This first-of-its-kind large-scale, multicenter prospective study demonstrated that AI assistance…
The DESTINY-Breast04 trial has recently demonstrated survival benefits of trastuzumab-deruxtecan (T-DXd) in metastatic breast cancer patients with low Human Epidermal Growth Factor Receptor 2 (HER2) expression. Accurate differentiation of HER2 scores has now become…
Continue Reading
What You Should Know:
– Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing…
Continue Reading
